Is Retatrutide FDA Approved? Status and Timeline

No. Retatrutide is not approved by the FDA, in any indication, at any dose. It is an investigational drug in active phase 3 development.

That answer usually prompts a second question, because retatrutide has published results in the New England Journal of Medicine and is widely sold online. Both of those things are true and neither is approval.

Current status

What the phase 2 data showed

The pivotal published result is a phase 2 trial of retatrutide for obesity, reported in the New England Journal of Medicine in 2023. It tested a triple agonist against placebo across a dose range over 48 weeks and reported dose-dependent weight reduction of a magnitude that drew considerable attention.

A separate 2026 Lancet report covers retatrutide in people with type 2 diabetes and inadequate glycaemic control, extending the evidence into a second population.

Why triple agonism is different

Retatrutide engages three receptors. Semaglutide engages one; tirzepatide engages two. The third — the glucagon receptor — is the notable addition, because glucagon agonism increases energy expenditure rather than only reducing intake.

Glucagon agonism is also why the safety question is not settled. Glucagon raises hepatic glucose output and affects lipid handling; adding it to two incretin agonists produces a metabolic profile with no marketed precedent. That is precisely the kind of question a phase 3 programme is designed to answer.

The retatrutide vs tirzepatide comparison goes into the mechanistic differences.

What approval would require

1. Completed phase 3 trials meeting predefined endpoints in the intended population.

2. A safety database large enough to characterise uncommon adverse events — typically thousands of patient-years.

3. A New Drug Application submitted with the full data package.

4. FDA review, typically ten to twelve months for a standard review.

5. Manufacturing inspection of the facilities that will make the marketed product.

6. An approved label defining indication, dosing, contraindications and warnings.

None of these steps has an announced completion date that anyone outside the sponsor can rely on. Any specific approval date circulating online is a projection, not information.

What "research use only" means here

Retatrutide sold online is supplied under a research-use-only designation — a legal category meaning not for human or veterinary use. It is not a quality grade and confers nothing.

The COA reading guide covers how to check identity, and the vendor selection guide covers evaluating suppliers.

The compounding route is closed

Semaglutide and tirzepatide were compounded legally during periods when FDA listed them as in shortage. When a shortage is resolved, that permission ends.

Retatrutide was never in that category. Compounding permission applies to approved drugs in shortage; an unapproved investigational drug cannot be compounded on that basis at all. Any offer described as compounded retatrutide is describing something with no legitimate route to exist.

Related questions

The full picture is in the FDA-approved peptides list, and the legality guide covers the buyer-side position. For what the compound is, see what is retatrutide and the retatrutide dosage chart.